Cancer Causes & Control

, Volume 17, Issue 4, pp 501–507 | Cite as

Artificial Lighting in the Industrialized World: Circadian Disruption and Breast Cancer

Special Section on Cancer and Rhythm Original Paper


Breast cancer risk is high in industrialized societies, and increases as developing countries become more Westernized. The reasons are poorly understood. One possibility is circadian disruption from aspects of modern life, in particular the increasing use of electric power to light the night, and provide a sun-free environment during the day inside buildings. Circadian disruption could lead to alterations in melatonin production and in changing the molecular time of the circadian clock in the suprachiasmatic nuclei (SCN). There is evidence in humans that the endogenous melatonin rhythm is stronger for persons in a bright-day environment than in a dim-day environment; and the light intensity necessary to suppress melatonin at night continues to decline as new experiments are done. Melatonin suppression can increase breast tumorigenesis in experimental animals, and altering the endogenous clock mechanism may have downstream effects on cell cycle regulatory genes pertinent to breast tissue development and susceptibility. Therefore, maintenance of a solar day-aligned circadian rhythm in endogenous melatonin and in clock gene expression by exposure to a bright day and a dark night, may be a worthy goal. However, exogenous administration of melatonin in an attempt to achieve this goal may have an untoward effect given that pharmacologic dosing with melatonin has been shown to phase shift humans depending on the time of day it’s given. Exogenous melatonin may therefore contribute to circadian disruption rather than alleviate it.


Breast cancer Circadian disruption Melatonin Shift work 


  1. 1.
    Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000: the global picture. Eur J Cancer 37:S4–S66CrossRefPubMedGoogle Scholar
  2. 2.
    Nagata C, Kawakami N, Shimizu H (1997) Trends in the incidence rate and risk factors for breast cancer in Japan. Breast Cancer Res Treat 44:75–82PubMedGoogle Scholar
  3. 3.
    Madigan MP, Ziegler RG, Benichou J, et al. (1995) Proportion of breast cancer cases in the United States explained by well-established risk factors. JNCI 87:1681–1685PubMedGoogle Scholar
  4. 4.
    Stevens RG, Rea MS (2001) Light in the built environment: potential role of circadian disruption in endocrine disruption and breast cancer. Cancer Causes Control 12:279–287CrossRefPubMedGoogle Scholar
  5. 5.
    Stevens RG, Davis S, Thomas DB, Anderson LE, Wilson BW (1992) Electric power, pineal function, and the risk of breast cancer. FASEB J 6:853–860PubMedGoogle Scholar
  6. 6.
    Pukkala E, Auvinen A, Wahlberg G (1995) Incidence of cancer among Finnish airline cabin attendants, 1967–92. Brit Med J 311:649–652PubMedGoogle Scholar
  7. 7.
    Tynes T, Hannevik M, Andersen A, et al. (1996) Incidence of breast cancer in Norwegian female radio and telegraph operators. Cancer Causes Control 7:197–204CrossRefPubMedGoogle Scholar
  8. 8.
    Hansen J (2001) Increased breast cancer risk among women who work predominantly at night. Epidemiology 12:74–77CrossRefPubMedGoogle Scholar
  9. 9.
    Davis S, Mirick DK, Stevens RG (2001) Night shift work, light at night, and risk of breast cancer. JNCI 93:1557–1562PubMedGoogle Scholar
  10. 10.
    Schernhammer ES, Laden L, Speizer FE, et al. (2001) Rotating night shifts and risk of breast cancer in women participating in the Nurses’ Health Study. JNCI 93:1563–1568PubMedGoogle Scholar
  11. 11.
    Hahn RA (1991) Profound bilateral blindness and the incidence of breast cancer. Epidemiology 2:208–210PubMedGoogle Scholar
  12. 12.
    Feychting M, Österlund B, Ahlbom A (1998) Reduced cancer incidence among the blind. Epidemiology 9:490–494PubMedGoogle Scholar
  13. 13.
    Verkasalo PK, Pukkala E, Stevens RG, Ojamo M, Rudanko S-L (1999) Inverse association between breast cancer incidence and degree of visual impairment in Finland. Brit J Cancer 80:1459–1460PubMedGoogle Scholar
  14. 14.
    Kliukiene J, Tynes T, Andersen A (2001) Risk of breast cancer among Norwegien women with visual impairment. Br J Cancer 84:397–399CrossRefPubMedGoogle Scholar
  15. 15.
    Stevens RG (1987) Review and Commentary. Electric power use and breast cancer a: hypothesis. Am J Epidemiol 125:556–561PubMedGoogle Scholar
  16. 16.
    Cohen M, Lippman M, Chabner B (1978) Role of the pineal gland in the aetiology and treatment of breast cancer. Lancet 2:814–881PubMedGoogle Scholar
  17. 17.
    Shah PN, Mhatre MC, Kothari LS (1984) Effect of melatonin on mammary carcinogenesis in intact and pinealectomized rats in varying photoperiods. Cancer Res 44:3403–3407PubMedGoogle Scholar
  18. 18.
    Brzezinski A (1997) Melatonin in humans. N Engl J Med 336:186–195CrossRefPubMedGoogle Scholar
  19. 19.
    Penny R, Stanczyk F, Goebelsmann U (1987) Melatonin: data consistent with a role in controlling ovarian function. J Endocrinol Invest 10:499–505PubMedGoogle Scholar
  20. 20.
    Kauppila A, Kilevä A, Pakarinen A, Vakkuri O (1987) Inverse seasonal relationship between melatonin and ovarian activity in humans in a region with a strong seasonal contrast in luminosity. J Clin Endocrinol Metab. 65:823–828PubMedGoogle Scholar
  21. 21.
    Baumgartner A, Dietzel M, Saletu B, et al. (1993) Influence of partial sleep deprivation on the secretion of thyrotropin, thyroid hormones, growth hormone, prolactin, luteinizing hormone, follicle stimulating hormone, and estradiol in healthy young women. Psychiatr Res 48:153–178CrossRefGoogle Scholar
  22. 22.
    Sanchez-Barcelo EJ, Cos S, Fernandez R, Mediavilla D (2003) Melatonin and mammary cancer: a short review. Endocr-Relat Cancer 10:153–159PubMedGoogle Scholar
  23. 23.
    Pawlikoski M, Kolomecka M, Wojtczak A, Karasek M (2002) Effects of six months melatonin treatment on sleep quality and serum concentrations of estrtadiol, cortosil dehydroepiandrosterone sulfate, and somatomedin C in elderly women. Neuroendocrinol Lett 23(suppl 1):17–19Google Scholar
  24. 24.
    Graham C, Cook MR, Gerkovich MM, Sastre A (2001) Examination of the melatonin hypothesis in women exposed at night to EMF and bright light. Environ Health Perspect 109:501–507PubMedGoogle Scholar
  25. 25.
    Schernhammer ES, Rosner B, Willett WC, Laden F, Colditz GA, Hankinson SE (2004) Epidemiology of uriniary melatonin in women and its relation to other hormones and night work. Cancer Epidemiol Biomark Prev 13:936–943Google Scholar
  26. 26.
    Stevens RG (2005). Circadian disruption and breast cancer: from melatonin to clock genes. Epidemiology 16:254–258PubMedGoogle Scholar
  27. 27.
    Dauchy RT, Blask DE, Sauer LA, Brainard GC, Krause JA (1999) Dim light during darkness stimulates tumor progression by enhancing tumor fatty acid uptake and metabolism. Cancer Lett 144:131–136CrossRefPubMedGoogle Scholar
  28. 28.
    Blask DE, Dauchy RT, Sauer LA, et al. (2003) Growth and fatty acid metabolism of human breast cancer (MCF-7) xenografts in nude rats: impact of constant light-induced nocturnal melatonin suppression. Breast Cancer Res Treat 79:313–320CrossRefPubMedGoogle Scholar
  29. 29.
    Travis RC, Allen DS, Fentiman IS, Key TJ (2004) Melatonin and breast cancer: a prospective study. J Natl Cancer Inst 96:475–482PubMedGoogle Scholar
  30. 30.
    Key TJ, for the The Endogenous Hormones, Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606–616Google Scholar
  31. 31.
    Fu L, Lee CC (2003) The circadian clock: pacemaker and tumor suppressor Nature Reviews. Cancer 3:350–361CrossRefPubMedGoogle Scholar
  32. 32.
    Blask DE, Pelletier DB, Hill SM, et al. (1991) Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: potential involvement of antiestrogenic mechanisms in vivo. J Cancer Res Clin Oncol 117:526–532CrossRefPubMedGoogle Scholar
  33. 33.
    Blask DE, Wilson ST, Zalatan F (1997) Physiological melatonin inhibition of human breast cancer cell growth in vitro evidence for a glutathione-mediated pathway. Cancer Res 57:1909–1914PubMedGoogle Scholar
  34. 34.
    Hill SM, Spriggs LL, Simon MA, Muraoka H, Blask DE (1992) The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen system. Cancer Lett 64:249–256CrossRefPubMedGoogle Scholar
  35. 35.
    Sephton S, Spiegel D (2003) Circadian disruption and cancer: a neuroendocrine-immune pathway from stress to disesase. Brain Behav Immun 17:321–328CrossRefPubMedGoogle Scholar
  36. 36.
    Amir S, Stewart J (1999) The effectiveness of light on the circadian clock is linked to its emotional value. Neurosci 88:339–345CrossRefGoogle Scholar
  37. 37.
    Wirz-Justice A, Krauchi K, Cajochen C, Danilenko KV, Renz C, Weber JM (2004) Evening melatonin and bright light administration induce additive phase shifts in dim light melatonin onset. J Pineal Res. 36:192–194CrossRefPubMedGoogle Scholar
  38. 38.
    Lewy AJ, Wehr TA, Goodwin FK, et al. (1980) Light suppresses melatonin secretion in humans. Science 210:1267–1269PubMedGoogle Scholar
  39. 39.
    Brainard GC, Hanifin JP, Greeson JM, et al. (2001) Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor. J Neurosci 21:6405–6412PubMedGoogle Scholar
  40. 40.
    Khalsa SBS, Jewett ME, Cajochen C, Czeisler CA (2003) A phase response curve to single bright light pulses in human subjects. J Physiol 549:945–952CrossRefPubMedGoogle Scholar
  41. 41.
    Hebert M, Martin SK, Lee C, Eastman CI (2002) The effects of prior light history on the suppression of melatonin by light in humans. J Pineal Res 33:198–203CrossRefPubMedGoogle Scholar
  42. 42.
    Jöchle W (1964) Trends in photophysiologic concepts. Ann NY Acad Sci 117:88–104Google Scholar
  43. 43.
    Lucas RJ, Freedman MS, Muñoz M, Garcia-Fernández JM, Foster RG (1999) Regulation of the mammalian pineal by non-rod, non-cone, ocular photoreceptors. Science 284:505–507CrossRefPubMedGoogle Scholar
  44. 44.
    Khaetski IK (1965) Effect of hypothalamo-pituitary lesions induced by constant illumination on development of induced mammary tumors in rats. Vopr Exp Oncol (Kiev) 1:87–93Google Scholar
  45. 45.
    Anisimov VN (2002) The light-dark regimen and cancer development. Neuroendocrinol Lett 23(suppl 2):28–36PubMedGoogle Scholar
  46. 46.
    Anderson LE, Morris JE, Sasser LB, Stevens RG (2000) Effect of constant light on DMBA mammary tumorigenesis in rats. Cancer Lett 148:121–126CrossRefPubMedGoogle Scholar
  47. 47.
    Russo IH, Russo J (1996) Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect 104:938–967PubMedGoogle Scholar
  48. 48.
    Russo IH, Mailo D, Morris JE, Anderson LE, Stevens RG (2004) Artificial Light and Circadian Rhythms: Influence of Age and Length of Exposure to Constant light on Mammary Gland Development and Cancer Risk. meeting abstract, ‘Emerging Topics in Breast Cancer and the Environment’. Organized by Breast Cancer and the Environment Research Centers, NIH. Princeton, NJ, November 4–6, 2004Google Scholar
  49. 49.
    Trichopoulos D (1990) Hypothesis: does breast cancer originate in utero?. Lancet 335:939–940CrossRefPubMedGoogle Scholar
  50. 50.
    Potischman N, Troisi R (1999) In utero and early life exposures in relation to risk of breast cancer. Cancer Causes Control 10:561–573CrossRefPubMedGoogle Scholar
  51. 51.
    Horne JA, Östberg O (1976) A self assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol 4:97–110PubMedGoogle Scholar
  52. 52.
    Griefahn B, Künemund C, Golka K, et al. (2002) Melatonin synthesis: a possible indicator of intolerance to shiftwork. Am J Indus Med 42:427–436Google Scholar
  53. 53.
    Griefahn B (2002) The validity of the temporal parameters of the daily rhythm of melatonin levels as an indicator of morningness. Chrono Int 19:561–577Google Scholar
  54. 54.
    Schernhammer ES, Laden F, Speizer FE, et al. (2003) Night-shift work and risk of colorectal cancer in the Nurses’ Health Study. J Natl Cancer Inst. 95:825–888PubMedGoogle Scholar
  55. 55.
    Zhang Y, Felson DT, Ellison RC, et al. (2001) Bone mass and the risk of colon cancer among postmenopausal women. Am J Epidemiol 153:31–37PubMedGoogle Scholar
  56. 56.
    Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD (2002) Postmenopausal hormone replacement therapy. JAMA 288:872–881PubMedGoogle Scholar
  57. 57.
    Stokkan KA, Yamazaki S, Tei H, Sakaki Y, Menaker M (2001) Entrainment of the circadian clock in the liver by feeding. Science 291:490–493CrossRefPubMedGoogle Scholar
  58. 58.
    Damioloa F, Minh NL, Preitner N, Kornmann B, Fleury-Olela F, Schibler U (2000) Restricted feeding uncouples circadian oscillators in periferl tissues from the central pacemaker in the suprachiasmatic nucleus. Gene Devlop 14:2950–2961Google Scholar
  59. 59.
    Baird TJ, Briscoe RJ, Vallett M, Vanecek SA, Holloway FA, Gauvin DV (1998) Phase-reponse curve for ethanol: alterations in circadian rhythms of temperature and activity in rats . Pharmacol Biochem Behav 61:303–315CrossRefPubMedGoogle Scholar
  60. 60.
    Allen GC, West JR, Chen WA, Earnest DJ (2004) Developmental alcohol exposure disrupts circadian regulation of BDNF in the rat suprachiasmatic nucleus. Neurotox Teratol 26:353–358Google Scholar
  61. 61.
    Farnell YZ, West JR, Chen WA, Allen GC, Earnest DJ (2004) Developmental alcohol exposure alters light-induced phase shifts of the circadian activity rhythm in rats. Alcohol Clin Exp Res 28:1020–1027PubMedGoogle Scholar
  62. 62.
    Beral V for the Collaborative Group on Hormonal Factors and Breast Cancer (2002) Alcohol, tobacco and breast cancer – collaborative reanalysis of individual data from 53 epidemiological studies, including 58515 women with breast cancer and 95067 women without the disease Brit J Cancer 87:1234–1245Google Scholar
  63. 63.
    Stevens RG, Hiatt RA (1987) Alcohol, melatonin, and breast cancer. N Engl J Med 317:1287Google Scholar
  64. 64.
    Stevens RG, Hilakivi-Clarke L (2001) Alcohol exposure in utero and breast cancer risk later in life. Alcohol Alcoholism 36:276–277CrossRefGoogle Scholar
  65. 65.
    Hilakivi-Clarke L, Cabanes A, De Assis S, Khan G, Shoemaker WJ, Stevens RG (2004). Low In Utero alcohol exposure increases mammary tumorigenesis in rats. Brit J Cancer 90:2224–2230Google Scholar
  66. 66.
    Moolgavkar SH, Day NE, Stevens RG (1980) Two-stage model for carcinogenesis: epidemiology of breast cancer in females. JNCI 65:559–569PubMedGoogle Scholar
  67. 67.
    Colditz GA, Rosner B (2000) Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses’ Health Study. Am J Epidemiol 152:950–964CrossRefPubMedGoogle Scholar
  68. 68.
    Zhu Y, Brown HN, Zhang Y, Stevens RG, Zheng T (2005) Period3 structural variation: a circadian biomarker associated with breast cancer in young women. Cancer Epidemiol Biomark Prev 14:268–270Google Scholar
  69. 69.
    Hill AB (1965) The environment and disease: association or causation? Proc Royal Soc Med 58:295–300Google Scholar
  70. 70.
    Kawachi I, Colditz GA, Stampfer MJ, et al. (1995) Prospective study of shift work and risk of coronary heart disease in women. Circulation 92:3178–3182PubMedGoogle Scholar
  71. 71.
    Hansen J (2001) Editorial: light at night, shiftwork, and breast cancer risk. JNCI 93:1513–1515PubMedGoogle Scholar

Copyright information

© Springer 2006

Authors and Affiliations

  1. 1.University of Connecticut Health CenterFarmingtonUSA

Personalised recommendations